Literature DB >> 29237387

Italian Association of Clinical Endocrinologists (AME) and Italian AACE Chapter Position Statement for Clinical Practice: Assessment of Response to Treatment and Follow-Up in Gastroenteropancreatic Neuroendocrine Neoplasms.

Franco Grimaldi1, Nicola Fazio2, Roberto Attanasio3, Andrea Frasoldati4, Enrico Papini5, Nadia Cremonini6, Maria V Davi7, Luigi Funicelli8, Sara Massironi9, Francesca Spada2, Vincenzo Toscano10, Annibale Versari11, Michele Zini4, Massimo Falconi12, Kjell Oberg13.   

Abstract

Well-established criteria for evaluating the response to treatment and the appropriate followup of individual patients are critical in clinical oncology. The current evidence-based data on these issues in terms of the management of gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are unfortunately limited. This document by the Italian Association of Clinical Endocrinologists (AME) on the criteria for the follow-up of GEP-NEN patients is aimed at providing comprehensive recommendations for everyday clinical practice based on both the best available evidence and the combined opinion of an interdisciplinary panel of experts. The initial risk stratification of patients with NENs should be performed according to the grading, staging and functional status of the neoplasm and the presence of an inherited syndrome. The evaluation of response to the initial treatment, and to the subsequent therapies for disease progression or recurrence, should be based on a cost-effective, risk-effective and timely use of the appropriate diagnostic resources. A multidisciplinary evaluation of the response to the treatment is strongly recommended and, at every step in the follow-up, it is mandatory to assess the disease state and the patient performance status, comorbidities, and recent clinical evolution. Local expertise, available technical resources and the patient preferences should always be evaluated while planning the individual clinical management of GEP-NENs. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  NEN; NET follow-up; Neuroendocrine tumors; carcinoidzzm321990syndrome; criteria of response; gastrinoma; imaging; insulinoma; markers; non-functioning NET.

Mesh:

Substances:

Year:  2018        PMID: 29237387     DOI: 10.2174/1871530318666171213145803

Source DB:  PubMed          Journal:  Endocr Metab Immune Disord Drug Targets        ISSN: 1871-5303            Impact factor:   2.895


  2 in total

1.  Complete remission of recurrent multiple insulin-producing neuroendocrine tumors of the pancreas with somatostatin analogs: a case report and literature review.

Authors:  Andreas Tartaglia; Giulia Busonero; Lorenza Gagliardi; Valentina Boddi; Federica Pieri; Maurizio Nizzoli
Journal:  Discov Oncol       Date:  2022-07-15

Review 2.  The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future.

Authors:  Virginia Liberini; Martin W Huellner; Serena Grimaldi; Monica Finessi; Philippe Thuillier; Alfredo Muni; Riccardo E Pellerito; Mauro G Papotti; Alessandro Piovesan; Emanuela Arvat; Désirée Deandreis
Journal:  Diagnostics (Basel)       Date:  2020-12-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.